Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2021-03-04 Annual Report
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
20-F
Annual Report FY 2020
2021-03-04 English
6-K
Regulatory Filings
2021-02-24 English
QIAGEN expands Supervisory Board with appointment of a new member
Board/Management Information Classification · 100% confidence The document is a press release dated February 22, 2021, announcing the appointment of Thomas Ebeling to the Supervisory Board of QIAGEN. This type of announcement concerns changes in the company's governing body (Board of Directors/Supervisory Board). Based on the provided definitions, this aligns directly with the 'Board/Management Information' category.
2021-02-23 English
SEC SCHEDULE 13G
Major Shareholding Notification
2021-02-11 English
QIAGEN beats outlook for fourth quarter and full-year 2020, reaffirms expectations for further growth in 2021
Earnings Release Classification · 100% confidence The document text consists of a detailed press release announcing strong financial results for the fourth quarter and full year of 2020, including key metrics like net sales, adjusted EPS, cash flow, and commentary from the CEO and CFO. It also reaffirms the outlook for 2021. This content structure—highlighting period results, providing management commentary, and detailing segment performance—is characteristic of an Earnings Release (ER). Although it contains comprehensive data, it is presented as an initial announcement of results, not the full, audited Annual Report (10-K) or a comprehensive Interim Report (IR). The length (over 4,600 characters) confirms it is more than a brief announcement, but its primary function is the initial release of earnings figures. Q4 2020
2021-02-10 English
6-K
Regulatory Filings
2021-02-09 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.